Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...
Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine ...
Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks ...
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
3d
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback